# Relay Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Relay Therapeutics, Inc.). ## Overview Relay Therapeutics, Inc. is a U.S.-based clinical-stage precision medicine company focused on discovering and developing small-molecule therapies for cancer and genetic diseases. The company’s work centers on its Dynamo platform, which combines computational and experimental methods to design drugs against protein targets that have been difficult to address with traditional approaches. ## Products & services • Dynamo® platform for structure-based drug discovery • Zovegalisib (RLY-2608) lead product candidate • Precision oncology drug candidates • Genetic disease drug candidates • Preclinical discovery and translational research programs - **Clinical-stage product candidates** (0%) — Small-molecule therapeutic candidates in clinical development, including the lead oncology program. - **Preclinical pipeline** (0%) — Discovery-stage programs in precision oncology and genetic diseases before first-in-human testing. - **Platform-enabled drug discovery** (0%) — Computational and experimental capabilities used to identify and optimize new drug candidates. - **Collaboration and license revenue** (100%) — Revenue from research collaborations, licenses, and related contractual arrangements. - Dynamo® platform for structure-based drug discovery - Zovegalisib (RLY-2608) lead product candidate - Precision oncology drug candidates - Genetic disease drug candidates - Preclinical discovery and translational research programs ## Customers Relay Therapeutics does not currently sell approved products to end patients; its economic counterparties are primarily collaboration partners and licensees. If its candidates are commercialized, the ultimate users would be physicians, healthcare providers, and third-party payors that influence prescribing and reimbursement in oncology and rare disease settings. - **Pharmaceutical collaboration partners** (primary) — Companies that license programs or collaborate on discovery and development to access Relay's platform and assets. - **Biotechnology partners** (primary) — Smaller drug developers that may co-develop or license programs for specific targets or indications. - **Healthcare providers and physicians** (secondary) — Potential prescribers of approved therapies, especially specialists in oncology and genetic disease. - **Third-party payors** (secondary) — Insurers and reimbursement bodies that would influence access and uptake after approval. - **Patients with precision medicine indications** (secondary) — Patients identified by molecular diagnostics for targeted treatment in oncology or genetic disease. - Pharmaceutical and biotech collaboration partners - License counterparties funding or sharing development work - Physicians and oncology specialists if products are approved - Third-party payors that determine reimbursement access - Patients with precision oncology or genetic disease targets ## Geography Relay Therapeutics is headquartered in Cambridge, Massachusetts and conducts research and development primarily from the United States. Its business also depends on foreign contract manufacturing organizations and other third parties, which creates operational exposure outside the U.S. even though the company is not yet commercializing products. - Headquartered in Cambridge, Massachusetts - Core research and development is U.S.-based - Relies on foreign CMOs for certain development materials - Clinical and regulatory activities may extend to foreign jurisdictions - No country-level revenue disclosure available ## Strategy Relay Therapeutics is focused on advancing a platform-led pipeline in precision oncology and genetic disease, using computational and experimental tools to improve target selection and molecule design. Its strategy is to move product candidates from discovery into clinical development and, where useful, through collaborations or licenses that support development and future commercialization. - **Advance clinical-stage programs** (short-term) — Clinical proof-of-concept is the key value driver for a biotech with no marketed products. - **Broaden the pipeline** (medium-term) — Multiple shots on goal reduce dependence on any single asset or indication. - **Leverage the Dynamo platform** (medium-term) — Platform productivity supports repeatable discovery and differentiation versus single-asset peers. - **Use partnerships selectively** (short-term) — Collaborations can provide validation, resources, and development support. - Advance zovegalisib and other clinical-stage candidates - Expand precision oncology and genetic disease pipeline - Use Dynamo platform to target hard-to-drug proteins - Pursue collaborations and licenses to support development - Build translational evidence to improve clinical success odds ## Risks Relay Therapeutics faces the typical risks of a clinical-stage biotech: trial failure, regulatory delays, and uncertainty around whether product candidates will ever reach approval. Its dependence on third-party manufacturers, collaborators, and external supply chains adds execution risk, while future commercialization would also introduce reimbursement, market access, and healthcare compliance risk. - **Failure in pivotal clinical development** [high] — The company has not yet successfully completed large-scale pivotal trials, so late-stage attrition remains a major risk. - **Regulatory approval risk** [high] — Even promising data may not translate into approval if regulators require additional evidence or identify safety issues. - **Third-party manufacturing and supply chain dependence** [high] — The company relies on foreign CMOs and external suppliers for investigational materials and APIs. - **Collaboration and licensing execution risk** [medium] — Milestones, reimbursements, and development support depend on counterparties and contract terms. - **Future commercialization and reimbursement risk** [medium] — If approved, uptake will depend on physician adoption and third-party payor coverage. - Clinical trials may fail to show safety or efficacy - Regulatory review can delay or block approval - Dependence on foreign CMOs can disrupt supply - Collaborations may not deliver expected milestones or funding - Future commercialization would face reimbursement and market access risk ## Accounting Relay Therapeutics’ accounting is shaped by collaboration revenue recognition, clinical development expense timing, and fair-value estimates. As a clinical-stage biotech, it also relies heavily on accruals for CRO/CMO services, prepaid expenses, and judgment around contingent or acquired research assets, which can make quarterly results uneven. - **ASC 606 collaboration revenue** — Genentech and Elevar-related revenue - **Clinical trial accruals** — R&D expense volatility - **Prepaid expenses and accrued R&D** — Quarterly operating expense timing - **Lease accounting** — G&A and facility cost presentation - **Fair value estimates** — Non-cash gains/losses and balance sheet estimates - Revenue recognition depends on collaboration contract terms - Clinical trial accruals can shift expense timing quarter to quarter - Prepaid and accrued R&D reflect vendor service progress - Fair value estimates may affect contingent consideration or acquired assets - Lease accounting affects office and lab occupancy costs --- *Last updated: 2026-04-29T04:53:16.438298+00:00*